## natureresearch

Corresponding author(s):	Zheng-Li Shi
Last updated by author(s):	Feb 21, 2020

## **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

Statistics	
For all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed	
☐ ☐ The exact san	nple size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement
A statement of	on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical Only common to	test(s) used AND whether they are one- or two-sided ests should be described solely by name; describe more complex techniques in the Methods section.
A description	of all covariates tested
A description	of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	ion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	thesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted is exact values whenever suitable.
For Bayesian	analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchic	al and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of e	effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated
•	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Software and o	:ode
Policy information abo	ut <u>availability of computer code</u>
Data collection	No software was used.
Data analysis	BWA (v0.712-r1039), Cutadapt (v1.18), Geneious (v11.0.3), MEGAHIT (v1.2.9), Clone Manager Professional Suite 8, MAFFT (v7.307), MGmapper (PE2.24 and SE2.24), PAL2NAL (version 14), Clustal Omega (version 1.2.4), RAxML (version 0.9.0)
	om algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data	
<ul><li>Accession codes, un</li><li>A list of figures that</li></ul>	ut <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: ique identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability
Sequence data that supp	ort the findings of this study have been deposited in GISAID with the accession no. EPI_ISL_402124 and EPI_ISL_402127-402131.
Field-speci	fic reporting
Please select the one b	elow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
X Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences

## Life sciences study design

Eukaryotic cell lines

Policy information about cell lines

Mycoplasma contamination

Commonly misidentified lines

Cell line source(s)

Authentication

(See ICLAC register)

All studies must dis	sclose on these points even when the disclosure is negative.
Sample size	Samples of seven pneumonia patients are available from the clinical hospital to be sent to Wuhan Institute of Virology for pathogen identification. The coronavirus genome sequences were obtained from 5 different patients and shared >99.9% identity, suggesting they were infected by the same virus. Therefore, the sample size is sufficient for conducting the following study which aims to identify and characterize the causative agent of this pneumonia outbreak.
Data exclusions	No data excluded
Replication	The authors guarantee the findings are reliably reproducible. At least three independent experiments were performed, which was stated in the text.
Randomization	Samples were chosen randomly.
Blinding	We were blinded when choosing samples.
We require informatis system or method lis  Materials & ex  n/a Involved in the system of the system or method lis  Eukaryotic Palaeonto Animals ar	cell lines  ogy  MRI-based neuroimaging  d other organisms  search participants
Antibodies	
Antibodies used	1. SARSr-CoV Rp3 NP antibody made in house; 2. Anti-Human IgG-HRP conjugated monoclonal antibody (Kyab Biotech Co., Ltd, Wuhan, China, dilution: 1:40000); 3. Anti-Rp3 NP-HRP conjugated (Kyab Biotech Co., Ltd, Wuhan, China, dilution: 1:4000); 4.FITC-labelled goat anti-mouse IgG H&L (Abcam, ab96879, dlilution 1:100); 5. cyanin 3-conjugated goat anti-rabbit IgG (Abcam, ab6939, dilution: 1:200); 6. mouse anti-S tag monoclonal antibody made in house
Validation	The house-made SARSr-CoV Rp3 NP antibodies and anti-S tag monoclonal antibody were validated in a WB. The cy3-conjugated anti-rabbit IgGs were validated in IFA. The FITC-labelled goat anti-mouse IgG H&L was validated in IHC.

1. African green monkey origin, Vero E6 cell; 2. Human lung cell Huh7; 3. Human HeLa cells. All cell lines werefrom

All monkey and human cells were from ATCC with authentication. The authentication was performed by microscope

morphology check, growth curve analysis or identity verification with STR analysis (for human cell lines).

We confirm that all cells were tested as mycoplasma negative.

No commonly misidentified cell lines were used.

## Human research participants

Policy information about <u>studies involving human research participants</u>

Population characteristics Participants were all 2019-nCoV infected patients.

Recruitment Samples were sent to Wuhan Institute of Virology by hospital for pathogen identification.

Ethics oversight Wuhan Jinyintan Hospital (the co-authored institution)

Note that full information on the approval of the study protocol must also be provided in the manuscript.